Russell Investments Group, Ltd. Rhythm Pharmaceuticals, Inc. Transaction History

Russell Investments Group, Ltd.

$60.3 Billion
Q2 2024

A detailed history of Russell Investments Group, Ltd. transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 2,010 shares of RYTM stock, worth $103,213. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,010

Previous 385 422.08%

Holding current value

$103,213

Previous $16,000 412.5%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$35.41 - $44.37 $57,541 - $72,101	1,625 Added 422.08%	2,010 $82,000
Q1 2024 May 08, 2024	BUY	$39.12 - $52.44 $15,061 - $20,189	385 New	385 $16,000
Q2 2023 Aug 10, 2023	BUY	$16.32 - $21.15 $17,952 - $23,265	1,100 New	1,100 $18,000
Q4 2020 Feb 08, 2021	SELL	$21.17 - $32.61 $124,712 - $192,105	-5,891 Closed	0 $0
Q3 2020 Nov 09, 2020	BUY	$18.13 - $30.61 $106,803 - $180,323	5,891 New	5,891 $127,000
Q2 2019 Aug 09, 2019	SELL	$21.11 - $28.48 $796,986 - $1.08 Million	-37,754 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$24.76 - $31.66 $79,033 - $101,058	3,192 Added 9.24%	37,754 $1.04 Million
Q4 2018 Feb 11, 2019	SELL	$24.11 - $31.34 $74,692 - $97,091	-3,098 Reduced 8.23%	34,562 $929,000
Q3 2018 Oct 26, 2018	SELL	$26.99 - $35.85 $573,348 - $761,561	-21,243 Reduced 36.06%	37,660 $1.1 Million
Q2 2018 Aug 08, 2018	SELL	$17.02 - $35.2 $145,061 - $300,009	-8,523 Reduced 12.64%	58,903 $1.84 Million
Q1 2018 May 11, 2018	BUY	$19.9 - $32.25 $1.34 Million - $2.17 Million	67,426 New	67,426 $1.34 Million

Others Institutions Holding RYTM

# of Institutions

178

Shares Held

69.1M

Call Options Held

467K

Put Options Held

224K

View Full List

About RHYTHM PHARMACEUTICALS, INC.

Ticker RYTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,720,000
Market Cap $2.86B
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...

More about RYTM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Account

Russell Investments Group, Ltd. Rhythm Pharmaceuticals, Inc. Transaction History